EVEREST MED (01952) holds a corporate development strategy exchange meeting to strengthen global layout and achieve leapfrog development strategy.

Hong Kong-listed innovative pharmaceutical company EVEREST MED (01952) held a strategic investor communication meeting on October 21st. The Honorary Chairman of the Board, Fu Wei, the Chairman and Executive Director of the Board, Wu Yifang, the Executive Director and CEO, Luo Yongqing, the Executive Director, President and CFO, He Ying, and other core management team members attended the meeting, providing a systematic introduction to the company's latest strategic planning, R&D progress, and mid-to-long-term development blueprint. New Chairman leading the company's long-term development The newly appointed Chairman of the Board, Wu Yifang, made his first appearance at the meeting. He will lead the board of directors in setting the company's strategic direction, providing strategic guidance to the executive team, driving and coordinating the implementation of key strategic initiatives, including strategic transactions, R&D innovation, and management of key stakeholders, empowering the company to improve management efficiency, strengthen global expansion progress, continuously promote the development and commercialization of more innovative drugs, and achieve the company's leapfrog development. It was also revealed at the meeting that EVEREST MED's controlling shareholder Concordia Capital will not reduce its stake in the company in the short term, expressing a firm confidence in the company's strategic prospects and long-term value. This statement further solidified the stability of the company's shareholder structure and injected confidence into the market. Deepening the "dual-drive" strategy, expanding into new blue ocean markets The strategic investor communication meeting further clarified EVEREST MED's strategic focus for the next stage. Under the guidance of the "dual-drive" strategy, the company will continue to enrich its product pipeline and maximize commercial value through independent research and development, licensed introductions, acquisitions, and capital empowerment. At the same time, the company will accelerate the promotion of self-developed products overseas and global expansion, benefiting more patients, and striving to become a leading global comprehensive biopharmaceutical company. Currently, EVEREST MED's product pipeline in core treatment areas such as nephrology, infectious diseases, and autoimmune diseases has entered a key harvest period. Nifurtimox and Eikast have established sustainable commercial hematopoietic capabilities, and Vissiplin (Eculizumab) is expected to become the next definitive blockbuster, bringing a new round of growth to the company. According to the company's latest data, Nifurtimox achieved sales revenue of nearly RMB 1 billion in January-September 2025. Following the mid-term performance announcement, the company again estimated that the full-year sales performance of Nifurtimox will reach RMB 1.2 to 1.4 billion, and maintain rapid growth in 2026, with a sales target of RMB 2.4 to 2.6 billion. In terms of independent research and development, the company relies on its leading mRNA tumor therapy vaccine platform and autologous CAR-T platform to continuously strengthen its self-developed technological barriers. Initiatives are actively being pursued in ophthalmology and other high-growth blue ocean fields to open up new growth curves for the medium to long term. Among them, EVER001 (Hepatone), a new generation covalent reversible BTK inhibitor with global rights, has demonstrated rapid, deep, and sustained immunological and clinical relief in 52 weeks complete data, with continued benefit after discontinuation. Some patients have maintained good efficacy in extended follow-up periods of up to 104 weeks, demonstrating the high safety and strong tolerance of Hepatone. The project has completed clinical POC (proof of concept) and is planned to initiate pivotal registration clinical trials for pMN and Phase II basket trials (including IgAN, FSGS, MCD) in 2026. Meanwhile, the company's autologous CAR-T project has completed preclinical proof of concept in non-human primate (NHP) models and is planning to start human clinical (FIH, first-in-human trial) studies before the end of 2025, and will submit a global IND (Investigational New Drug application) in 2026 and carry out multiple IITs (Investigator-initiated Trials). According to the plan, in the next 6 to 12 months, the company plans to introduce more than 3 heavyweight products. The potential peak domestic sales of the introduced products are expected to exceed RMB 10 billion, adding to the existing product matrix, with the overall peak domestic sales expected to surpass RMB 20 billion. Strategic synergy with I-Mab: Using VIS-101 as a cooperation paradigm to introduce more products It is worth noting that I-Mab recently announced the introduction of the eye diseases treatment product VIS-101 and signed an intention letter for cooperation and development in Greater China, South Korea, and Southeast Asia with EVEREST MED. As the largest shareholder of I-Mab, EVEREST MED will use this cooperation as a starting point to further strengthen the collaboration between the two parties in innovative research and international development, exploring more opportunities for cooperation in high-potential assets. VIS-101 is an innovative bispecific biologic targeting VEGF-A and ANG2, with stronger molecular activity, and is expected to provide more lasting efficacy for patients with wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) compared to existing standard therapies. Currently, VIS-101 has completed preliminary safety and dose escalation studies in the US and China, and a randomized dose-ranging Phase II study has been completed in China, with conditions expected to conduct Phase III trials in 2026. The global market for anti-VEGF ophthalmic drugs has a broad space, with its scale reaching approximately $23 billion in 2024 and expected to exceed $40 billion by 2030, showcasing promising prospects for innovative therapies. In this context, EVEREST MED is formally entering the high-growth "blue ocean" field of ophthalmology by introducing VIS-101, a potential best-in-class product of its kind, further expanding its layout in core treatment areas, such as kidney disease, autoimmunity, and infectious diseases, and forming strategic synergy with its existing product portfolio. Leveraging its excellent commercial platform to maximize value. In the future, both parties will fully synergize clinical development resources to accelerate the simultaneous development of VIS-101 in the Asia-Pacific and the US, enhancing R&D efficiency and globalization progress. Using VIS-101 as a cooperation paradigm, EVEREST MED will actively explore synergistic opportunities with I-Mab in other high-potential treatment areas, continuously strengthen EVEREST MED's comprehensive competitiveness and strategic layout in the global innovative pharmaceutical field. Industry analysts have stated that this meeting comprehensively demonstrates EVEREST MED's systematic progress in capital empowerment, innovative breakthroughs, and global expansion. As the core pipeline enters the value realization stage, combined with the continuous empowerment of the self-developed platform, the company's competitiveness in the global innovative pharmaceutical field will further enhance, steadily advancing towards the goal of becoming a leading global comprehensive biopharmaceutical enterprise.